*NOTE: One or more of these trial phases may have been completed since publication of this article.

Have you ever considered participating in a clinical trial? Clinical trials are essential for researchers to develop new treatments and learn if they are safe and effective. Though it may feel scary, participants often speak of how gratifying it is to help improve the lives of current and future patients all over the world. Some clinical trials also offer financial compensation for time and travel. If you have Immunoglobulin A Nephropathy (IgAN), read more about current clinical trials to see if you or you are eligible.* 

The Align Study

The ALIGN study is testing a new medication called atrasentan in IgAN patients, which has the potential to reduce the amount of protein in urine and preserve kidney function. Participants will receive either atrasentan or a placebo. Check your eligibility and apply to learn more. 

The ALN-CC5 IgAn Trial

In IgAN patients, a protein builds up in the kidney that leads to kidney damage as the protein leaks into the urine. The ALN-CC5 IgAN trial is investigating a medication called cemdisiran to determine if it lowers kidney inflammation and urine leakage. 

The ADU-CL-19 Trial

The ADU-CL-19 Trial is testing a medication called BION-1301 in patients whose IgAN was confirmed via biopsy in the last 10 years. BION-1301 has the potential to decrease the amount of autoimmune proteins in your kidney. All participants will receive BION-1301 subcutaneously for a treatment period of 52 weeks.

The APPLAUSE-IgAN Trial

The APPLAUSE-IgAN Trial is evaluating a new oral drug called Iptacopan or LNP023. Following the screening period, eligible participants will receive either the drug or a placebo for a treatment period of two years. All participants will continue taking their existing supportive drugs (ACE inhibitors, ARBs, etc.) throughout the treatment period. 

The Artemis-IgAN Trial

The Artemis-IgAN Trial is evaluating the safety and efficacy of a medication called narsoplimab. Participants will receive either narsomplimab or a placebo for 12 weeks. The primary outcome measure is a reduction in urine protein excretion at 36 weeks. Check to see if you are eligible. 

The EPPIK Study

The EPPIK study is for an investigational drug called sparsentan for the potential treatment of IgAN and other rare kidney diseases in children between the ages of one and 17. Researchers expect to enroll approximately 57 participants globally. 

The FREEDOM-1 Study

Did you receive a kidney transplant from a living donor? The FREEDOM-1 Study is recruiting participants to evaluate a new treatment that could potentially eliminate the need for anti-rejection drugs, which are commonly needed post-transplant. Check to see if you are eligible. 

The ALXN1210-NEPH-202 Study

The ALXN1210-NEPH-202 Study is evaluating the safety and effectiveness of a new medication called ravulizumab in treating individuals with either lupus nephritis (LN) or IgAN. Participants will receive either the drug or a placebo intravenously for the 26-week initial evaluation period.

VT-001-0050 ORIGIN Trial

The Phase 2b ORIGIN Trial is researching a medication called atacicept in IgAN patients. The goal is to halt overproduction of an abnormal antibody called Gd-IgA1, which would reduce the production of autoantibodies and lower inflammation. Participation in the trial would require a commitment of two and a half years.

The VISIONARY Study

The VISIONARY Study is recruiting participants to evaluate an investigational drug, which aims to treat the cause and manage the symptoms of IgA nephropathy. Either the drug or a placebo will be administered via injection every 28 days (for a total of 26 doses) during the treatment period. 

*Soin, G. (2022, June 17). CLINICAL TRIALS. IGA Nephropathy Foundation of America. https://igan.org/clinical-trials/